20-F Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 FY 2016

Filing Information

Form Type	20-F
Accession Number	`0001193125-17-045463`
Period End Date	20161231
Filing Date	20170215
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	teva-20161231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 95 Income Statement 72 Cash Flow Statement 138 Stockholders Equity 35 Comprehensive Income 27

Balance Sheet 95 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.02B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Treasury, shares	`TreasuryStockShares`	108.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Treasury, shares	`TreasuryStockShares`	108.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.04B	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.52B	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.35B	USD	Point-in-time
Inventories	`InventoryNet`	$3.97B	USD	Point-in-time
Preferred Stock Shares Issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Preferred Stock Shares Issued	`PreferredStockSharesIssued`	3.40M	shares	Point-in-time
Inventories	`InventoryNet`	$4.95B	USD	Point-in-time
Deferred income taxes, see note 1	`DeferredTaxAssetsNetCurrent`	-	USD	Point-in-time
Preferred Stock Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred Stock Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Deferred income taxes, see note 1	`DeferredTaxAssetsNetCurrent`	$735.00M	USD	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	-	USD	Point-in-time
Preferred Stock Par Or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Preferred Stock Par Or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	$841.00M	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$910.00M	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$1.36B	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$491.00M	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$1.29B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.40B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$16.96B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.24B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$2.34B	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$725.00M	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$250.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.54B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$8.07B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$21.49B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$7.67B	USD	Point-in-time
Goodwill	`Goodwill`	$44.41B	USD	Point-in-time
Goodwill	`Goodwill`	$18.41B	USD	Point-in-time
Goodwill	`Goodwill`	$19.02B	USD	Point-in-time
Total assets	`Assets`	$54.23B	USD	Point-in-time
Total assets	`Assets`	$92.89B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.28B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.58B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$7.84B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$6.60B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.16B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.92B	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$859.00M	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$710.00M	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$1.68B	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$3.40B	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	$116.00M	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	-	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$867.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$510.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$18.52B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.01B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$1.75B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$5.21B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$1.20B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$1.64B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$8.36B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$32.52B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$11.30B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$39.38B	USD	Point-in-time
Total liabilities	`Liabilities`	$57.90B	USD	Point-in-time
Total liabilities	`Liabilities`	$24.31B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.62B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.29B	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$52.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.41B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$17.76B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$13.61B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$14.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-91.00M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.34B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.16B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.23B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.19B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$29.77B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$33.34B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$158.00M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.66B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$22.64B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$54.23B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$92.89B	USD	Point-in-time

Income Statement 72 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`SalesRevenueNet`	$19.65B	USD	Annual
Net revenues	`SalesRevenueNet`	$21.90B	USD	Annual
Net revenues	`SalesRevenueNet`	$20.27B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$10.04B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$8.30B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$9.22B	USD	Annual
Gross profit	`GrossProfit`	$11.86B	USD	Annual
Gross profit	`GrossProfit`	$11.06B	USD	Annual
Gross profit	`GrossProfit`	$11.36B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.52B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.49B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$2.11B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.48B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.86B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.86B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.24B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.24B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.22B	USD	Annual
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$699.00M	USD	Annual
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$1.13B	USD	Annual
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$650.00M	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$631.00M	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$899.00M	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$-111.00M	USD	Annual
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	$900.00M	USD	Annual
Operating income	`OperatingIncomeLoss`	$2.15B	USD	Annual
Operating income	`OperatingIncomeLoss`	$3.95B	USD	Annual
Operating income	`OperatingIncomeLoss`	$3.35B	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-1.33B	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-313.00M	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-1.00B	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$824.00M	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$3.64B	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$2.35B	USD	Annual
Income taxes	`IncomeTaxExpenseBenefit`	$591.00M	USD	Annual
Income taxes	`IncomeTaxExpenseBenefit`	$521.00M	USD	Annual
Income taxes	`IncomeTaxExpenseBenefit`	$634.00M	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-121.00M	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$8.00M	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-5.00M	USD	Annual
Net income	`ProfitLoss`	$3.04B	USD	Annual
Net income	`ProfitLoss`	$311.00M	USD	Annual
Net income	`ProfitLoss`	$1.60B	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-13.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$9.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-18.00M	USD	Annual
Net income attributable to Teva	`NetIncomeLoss`	$329.00M	USD	Annual
Net income attributable to Teva	`NetIncomeLoss`	$3.06B	USD	Annual
Net income attributable to Teva	`NetIncomeLoss`	$1.59B	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$15.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$261.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	-	USD	Annual
Net income attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$1.57B	USD	Annual
Net income attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$68.00M	USD	Annual
Net income attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$3.06B	USD	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	955.00M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	853.00M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	855.00M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.00M	shares	Point-in-time
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	864.00M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	961.00M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	4.00M	shares	Point-in-time
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	858.00M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.00M	shares	Point-in-time
Basic	`EarningsPerShareBasic`	$1.84	USD	Annual
Basic	`EarningsPerShareBasic`	$3.58	USD	Annual
Basic	`EarningsPerShareBasic`	$0.07	USD	Annual
Diluted	`EarningsPerShareDiluted`	$1.82	USD	Annual
Diluted	`EarningsPerShareDiluted`	$3.56	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.07	USD	Annual

Cash Flow Statement 138 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$3.04B	USD	Annual
Net income	`ProfitLoss`	$311.00M	USD	Annual
Net income	`ProfitLoss`	$1.60B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.31B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.52B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.51B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-967.00M	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-290.00M	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-1.22B	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$15.00M	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$237.00M	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-226.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	-	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$35.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$422.00M	USD	Annual
Translation adjustments due to Venezuela devaluations	`VenezuelaImpairmentOfNetMonetaryAssets`	-	USD	Annual
Translation adjustments due to Venezuela devaluations	`VenezuelaImpairmentOfNetMonetaryAssets`	-	USD	Annual
Translation adjustments due to Venezuela devaluations	`VenezuelaImpairmentOfNetMonetaryAssets`	$603.00M	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$361.00M	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$1.65B	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$387.00M	USD	Annual
Impairment Of Equity Investment - Net	`ImpairmentOfInvestments`	-	USD	Annual
Impairment Of Equity Investment - Net	`ImpairmentOfInvestments`	-	USD	Annual
Impairment Of Equity Investment - Net	`ImpairmentOfInvestments`	$124.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$95.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$124.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$117.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$14.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-24.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-146.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-736.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-140.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-6.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$764.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-1.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$86.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.13B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.22B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.54B	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$36.15B	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$363.00M	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$3.31B	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$929.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$772.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$901.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$324.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$2.00B	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$481.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$196.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$524.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$2.00B	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$5.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$212.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$30.00M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.45B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.57B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-35.74B	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$329.00M	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$3.29B	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	-	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$3.29B	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Point-in-time
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	$500.00M	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	$439.00M	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$29.00M	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-385.00M	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$2.00B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.16B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.16B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.30B	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	-	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$255.00M	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	-	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$514.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$388.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$35.00M	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$2.10B	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	-	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$25.25B	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$999.00M	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$2.52B	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$839.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-169.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-178.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-9.00M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$4.80B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$25.22B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.38B	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-62.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-114.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-660.00M	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-5.96B	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$4.72B	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$1.19B	USD	Annual
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.04B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.04B	USD	Point-in-time
Cash paid during the year for Interest	`InterestPaid`	$243.00M	USD	Annual
Cash paid during the year for Interest	`InterestPaid`	$294.00M	USD	Annual
Cash paid during the year for Interest	`InterestPaid`	$290.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$802.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$341.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$675.00M	USD	Annual
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	$5.07B	USD	Point-in-time
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	-	USD	Point-in-time
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	-	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	$1.82B	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	-	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	-	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	-	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	-	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	$302.00M	USD	Point-in-time
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$710.00M	USD	Annual
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$763.00M	USD	Annual
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$343.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$129.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$372.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$230.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-36.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$87.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-517.00M	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-614.00M	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$640.00M	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-12.00M	USD	Annual
Inventory Step Up	`InventoryStepUp`	-	USD	Annual
Inventory Step Up	`InventoryStepUp`	-	USD	Annual
Inventory Step Up	`InventoryStepUp`	$381.00M	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$1.22B	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$967.00M	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$290.00M	USD	Annual

Stockholders Equity 35 line items

Line Item	Tag	Value	Unit	Period
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	$388.00M	USD	Annual
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	$514.00M	USD	Annual
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	$35.00M	USD	Annual
Ordinary shares issuance value	`StockIssuedDuringPeriodValueNewIssues`	$3.29B	USD	Annual
Ordinary shares issuance value	`StockIssuedDuringPeriodValueNewIssues`	$5.39B	USD	Annual
Ordinary shares issuance	`StockIssuedDuringPeriodSharesNewIssues`	5.40M	shares	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$117.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$159.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$95.00M	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$1.16B	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$1.30B	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$1.16B	USD	Annual
Purchase of treasury shares	`StockIssuedDuringPeriodValueTreasuryStockReissued`	$-500.00M	USD	Annual
Purchase of treasury shares	`StockIssuedDuringPeriodValueTreasuryStockReissued`	$-439.00M	USD	Annual
Mcps Issuance	`MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues`	$3.29B	USD	Point-in-time
Mcps Issuance	`MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues`	$329.00M	USD	Point-in-time
Accrued Dividends to preferred shareholders	`DividendsPreferredStockCash`	$15.00M	USD	Annual
Acquisition of non-controlling interests	`MinorityInterestDecreaseFromRedemptions`	$103.00M	USD	Annual
Other	`OtherEquity`	$-15.00M	USD	Point-in-time
Other	`OtherEquity`	$-4.00M	USD	Point-in-time
Other	`OtherEquity`	$7.00M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$22.64B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$22.64B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-953.00M	USD	Annual
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$984.00M	USD	Annual
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$1.78B	USD	Annual
Dividends To Preferred Shareholders	`DividendsToPreferredShareholders`	$-261.00M	USD	Annual
Disposition Of Non Controlling Interests	`DispositionOfNonControllingInterests`	$-14.00M	USD	Annual
Transactions With Non Controlling Interests	`TransactionsWithNonControllingInterests`	$1.68B	USD	Annual

Comprehensive Income 27 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$3.04B	USD	Annual
Net income	`ProfitLoss`	$311.00M	USD	Annual
Net income	`ProfitLoss`	$1.60B	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.10B	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-445.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.44B	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$477.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-237.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-135.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$319.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-12.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-319.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-23.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$35.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-43.00M	USD	Annual
Total other comprehensive loss	`TotalOtherComprehensiveIncomeLoss`	$-613.00M	USD	Annual
Total other comprehensive loss	`TotalOtherComprehensiveIncomeLoss`	$-1.26B	USD	Annual
Total other comprehensive loss	`TotalOtherComprehensiveIncomeLoss`	$-1.26B	USD	Annual
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-953.00M	USD	Annual
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$984.00M	USD	Annual
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$1.78B	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$19.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$78.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$-8.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-875.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.80B	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$976.00M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.